Chaperone-Mediated Autophagy Suppresses Apoptosis via Regulation of the Unfolded Protein Response during Chronic Obstructive Pulmonary Disease Pathogenesis.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 05 02 2020
accepted: 29 06 2020
pubmed: 24 7 2020
medline: 23 3 2021
entrez: 24 7 2020
Statut: ppublish

Résumé

Cigarette smoke (CS) induces accumulation of misfolded proteins with concomitantly enhanced unfolded protein response (UPR). Increased apoptosis linked to UPR has been demonstrated in chronic obstructive pulmonary disease (COPD) pathogenesis. Chaperone-mediated autophagy (CMA) is a type of selective autophagy for lysosomal degradation of proteins with the KFERQ peptide motif. CMA has been implicated in not only maintaining nutritional homeostasis but also adapting the cell to stressed conditions. Although recent papers have shown functional cross-talk between UPR and CMA, mechanistic implications for CMA in COPD pathogenesis, especially in association with CS-evoked UPR, remain obscure. In this study, we sought to examine the role of CMA in regulating CS-induced apoptosis linked to UPR during COPD pathogenesis using human bronchial epithelial cells (HBEC) and lung tissues. CS extract (CSE) induced LAMP2A expression and CMA activation through a Nrf2-dependent manner in HBEC. LAMP2A knockdown and the subsequent CMA inhibition enhanced UPR, including CHOP expression, and was accompanied by increased apoptosis during CSE exposure, which was reversed by LAMP2A overexpression. Immunohistochemistry showed that Nrf2 and LAMP2A levels were reduced in small airway epithelial cells in COPD compared with non-COPD lungs. Both Nrf2 and LAMP2A levels were significantly reduced in HBEC isolated from COPD, whereas LAMP2A levels in HBEC were positively correlated with pulmonary function tests. These findings suggest the existence of functional cross-talk between CMA and UPR during CSE exposure and also that impaired CMA may be causally associated with COPD pathogenesis through enhanced UPR-mediated apoptosis in epithelial cells.

Identifiants

pubmed: 32699159
pii: jimmunol.2000132
doi: 10.4049/jimmunol.2000132
doi:

Substances chimiques

NF-E2-Related Factor 2 0
Smoke 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1256-1267

Informations de copyright

Copyright © 2020 by The American Association of Immunologists, Inc.

Auteurs

Yusuke Hosaka (Y)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Jun Araya (J)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan; araya@jikei.ac.jp.

Yu Fujita (Y)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Tsukasa Kadota (T)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Kazuya Tsubouchi (K)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Masahiro Yoshida (M)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Shunsuke Minagawa (S)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Hiromichi Hara (H)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Hironori Kawamoto (H)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Naoaki Watanabe (N)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Akihiko Ito (A)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Akihiro Ichikawa (A)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Nayuta Saito (N)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Keitaro Okuda (K)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Junko Watanabe (J)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Daisuke Takekoshi (D)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Hirofumi Utsumi (H)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Mitsuo Hashimoto (M)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Hiroshi Wakui (H)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Saburo Ito (S)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Takanori Numata (T)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Shohei Mori (S)

Division of Chest Diseases, Department of Surgery, Jikei University School of Medicine, Tokyo 104-8461, Japan; and.

Hideki Matsudaira (H)

Division of Chest Diseases, Department of Surgery, Jikei University School of Medicine, Tokyo 104-8461, Japan; and.

Jun Hirano (J)

Division of Chest Diseases, Department of Surgery, Jikei University School of Medicine, Tokyo 104-8461, Japan; and.

Takashi Ohtsuka (T)

Division of Chest Diseases, Department of Surgery, Jikei University School of Medicine, Tokyo 104-8461, Japan; and.

Katsutoshi Nakayama (K)

Department of Respiratory Medicine, Akita University Graduate School of Medicine, Akita 010-8543, Japan.

Kazuyoshi Kuwano (K)

Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 104-8461, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH